Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2
Authors
Keywords
COVID-19, SARS-CoV-2, spike glycoprotein, IgM, IgA, IgG, neutralization, convalescent plasma
Journal
Cell Reports
Volume 34, Issue 9, Pages 108790
Publisher
Elsevier BV
Online
2021-02-11
DOI
10.1016/j.celrep.2021.108790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia
- (2020) Khalaf Kridin et al. AUTOIMMUNITY REVIEWS
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia
- (2020) Philippe Guilpain et al. ANNALS OF THE RHEUMATIC DISEASES
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020
- (2020) Ranawaka APM Perera et al. Eurosurveillance
- COVID-19 in Rheumatic Disease Patients on Immunosuppressive Agents
- (2020) Saika Sharmeen et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Convergent antibody responses to SARS-CoV-2 in convalescent individuals
- (2020) Davide F. Robbiani et al. NATURE
- Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
- (2020) Quan-Xin Long et al. NATURE MEDICINE
- Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
- (2020) Philip J. M. Brouwer et al. SCIENCE
- B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran
- (2020) Farinaz Safavi et al. Multiple Sclerosis and Related Disorders
- COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series
- (2020) Richard Hughes et al. Multiple Sclerosis and Related Disorders
- Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals
- (2020) Guillaume Beaudoin-Bussières et al. mBio
- Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
- (2020) Jeffrey Seow et al. Nature Microbiology
- Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset
- (2020) Josée Perreault et al. BLOOD
- Enhanced SARS-CoV-2 neutralization by dimeric IgA
- (2020) Zijun Wang et al. Science Translational Medicine
- Human IgA binds a diverse array of commensal bacteria
- (2019) Delphine Sterlin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins
- (2009) Isabelle St-Amour et al. CLINICAL IMMUNOLOGY
- Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies
- (2008) Elke S Bergmann-Leitner et al. MALARIA JOURNAL
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started